Implanet SA (IM11) Stock Price & Analysis
IM11 Stock Chart & Stats
- Day’s Range
- EUR 0.14 - EUR 0.14
- 52-Week Range
- EUR 0.14 - EUR 0.27
- Previous Close
- EUR 0.14
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 21.40M
- Enterprise Value
- EUR 28.61M
- Total Cash (Recent Filing)
- EUR 1.01M
- Total Debt (Recent Filing)
- EUR 5.46M
- Price to Earnings (P/E)
- ―
- Beta
- -0.31
- Next Earnings
- Mar 09, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The strong rebound in revenue indicates improving commercial traction for Implanet’s orthopedic and spine products. Sustained top-line expansion can broaden the installed customer base, support operating leverage, and provide a foundation for future earnings improvement if growth continues.
Gross Margin Expansion
The material gross-margin improvement suggests a more favorable product mix, pricing profile, or sales economics. If maintained, higher gross profit per sale should improve the company’s ability to fund commercial activity and absorb fixed costs as revenue scales.
Improving Operating Cash Flow
Although operating cash flow remains negative, the sharp year-over-year improvement shows reduced cash consumption from operations. Continued progress toward break-even could lessen funding pressure and increase financial flexibility as the company’s revenue base expands.
Bears Say
Persistent Losses
Persistent operating and net losses show that revenue growth and better gross margins have not yet translated into a sustainable earnings model. Until profitability improves, Implanet may have less capacity to reinvest, absorb setbacks, or build equity internally.
High Leverage
The very thin equity cushion leaves the company financially sensitive to further losses and execution shortfalls. High leverage can constrain capital allocation, increase dependence on financing, and reduce resilience while the business is still working toward profitability.
Negative Free Cash Flow
Ongoing negative free cash flow means the company is not yet funding its investment and operating needs through internally generated cash. Continued cash deficits can require external funding and may limit the pace or reliability of strategic growth initiatives.
Implanet SA News
IM11 FAQ
What was Implanet SA’s price range in the past 12 months?
What is Implanet SA’s market cap?
When is Implanet SA’s upcoming earnings report date?
How were Implanet SA’s earnings last quarter?
Is Implanet SA overvalued?
Does Implanet SA pay dividends?
What is Implanet SA’s EPS estimate?
How many shares outstanding does Implanet SA have?
What happened to Implanet SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Implanet SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Implanet SA
Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ludovic Lastennet
- Employees
- 49
- Website
- www.implanet.com
- Address
- Technopole Bordeaux Montesquieu, Martillac, NA, 33650, FR
Implanet SA (IM11) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 2 | 12 |
| Technical Analysis | 6 | 2 | 1 |
| Moving Averages | 1 | 0 | 11 |


